Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Phase 1 Trial of Bemcentinib (BGB324), a First-in-class, Selective AXL Inhibitor, with Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Sheena Bhalla,Farjana J. Fattah,Chul Ahn,Jessica Williams,Alyssa Macchiaroli,Jonathan Padro,Meredith Pogue,Jonathan E. Dowell,William C. Putnam,Nigel McCracken,David Micklem,Rolf A. Brekken,David E. Gerber

LUNG CANCER（2023）

Cited 8|Views28
Key words
Advanced NSCLC,AXL,Bemcentinib,Docetaxel,Tyrosine kinase inhibitors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined